Prognosis of small-cell lung cancer since the introduction of amrubicin.

Medical Oncology
Hidekazu SuzukiIchiro Kawase

Abstract

Several studies have demonstrated the effectiveness of amrubicin (AMR) in small-cell lung cancer (SCLC). This study aimed to assess the change in the prognosis of SCLC before and after the commercial availability of AMR. We retrospectively analyzed data from 243 patients with newly diagnosed SCLC. Patients diagnosed before the start of the sale of AMR (January 1997-May 2002) constituted Group A, and patients diagnosed after its introduction (December 2002-December 2006), constituted Group B. The overall survival and demographic factors of the 2 groups were compared. Similar comparisons were also performed on subsets. Median survival time (MST) was 313 days for Group A and 388 days for Group B (P=0.031). Group B with limited disease (LD) demonstrated a significantly longer median survival time (321 vs. 506 days; P=0.022) than Group A, whereas no significant difference was noted between the groups of patients with extensive disease (ED) (296 vs. 280 days; P=0.895). In the subset of refractory relapse of LD, the MST was clearly longer in Group B than in Group A (220 vs. 321 days; P<0.001). Multivariate analysis for LD patients indicated that performance status (hazard ratio 2.072; P=0.003) and commercial availability of AMR (0.596...Continue Reading

References

Jan 23, 1999·Japanese Journal of Cancer Research : Gann·M HanadaT Yamaoka
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J von PawelR Gralla
Jan 11, 2002·The New England Journal of Medicine·Kazumasa NodaUNKNOWN Japan Clinical Oncology Group
Nov 20, 2003·Clinical Lung Cancer·Koji TakedaMasahiro Fukuoka
Sep 30, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ramaswamy GovindanJay Piccirillo
Dec 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mary E R O'BrienTheresa Crofts
Dec 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sayaka OnodaUNKNOWN Thoracic Oncology Research Group Study 0301
Aug 19, 2007·The New England Journal of Medicine·Ben SlotmanUNKNOWN EORTC Radiation Oncology Group and Lung Cancer Group
Oct 16, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Akira InoueToshihiro Nukiwa

❮ Previous
Next ❯

Citations

Aug 2, 2013·The Cochrane Database of Systematic Reviews·Vinicius CavalheriKylie Hill

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Haruyasu MurakamiTomohide Tamura
Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Takashi HiroseMitsuru Adachi
International Journal of Cancer. Journal International Du Cancer
Jacques FerlayDonald Maxwell Parkin
© 2021 Meta ULC. All rights reserved